دورية أكاديمية
أعرض في EDS

The potential of cell-free and exosomal microRNAs as biomarkers in liquid biopsy in patients with prostate cancer.

التفاصيل البيبلوغرافية
العنوان: The potential of cell-free and exosomal microRNAs as biomarkers in liquid biopsy in patients with prostate cancer.
المؤلفون: de Nóbrega M; Department of General Biology, Laboratory of Mutagenesis and Oncogenetics, Center of Biologic Sciences, State University of Londrina, Rodovia Celso Garcia Cid, PR-445, Km 380-University Campus, Londrina, PR, CEP 86057-970, Brazil., Dos Reis MB; Barretos Cancer Hospital (Molecular Oncology Research Center), Barretos, SP, CEP 14784-400, Brazil., Pereira ÉR; Department of General Biology, Laboratory of Mutagenesis and Oncogenetics, Center of Biologic Sciences, State University of Londrina, Rodovia Celso Garcia Cid, PR-445, Km 380-University Campus, Londrina, PR, CEP 86057-970, Brazil., de Souza MF; Department of General Biology, Laboratory of Mutagenesis and Oncogenetics, Center of Biologic Sciences, State University of Londrina, Rodovia Celso Garcia Cid, PR-445, Km 380-University Campus, Londrina, PR, CEP 86057-970, Brazil., de Syllos Cólus IM; Department of General Biology, Laboratory of Mutagenesis and Oncogenetics, Center of Biologic Sciences, State University of Londrina, Rodovia Celso Garcia Cid, PR-445, Km 380-University Campus, Londrina, PR, CEP 86057-970, Brazil. ilcecolus@gmail.com.
المصدر: Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2022 Oct; Vol. 148 (10), pp. 2893-2910. Date of Electronic Publication: 2022 Aug 04.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 7902060 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-1335 (Electronic) Linking ISSN: 01715216 NLM ISO Abbreviation: J Cancer Res Clin Oncol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Berlin ; New York : Springer-Verlag.
مواضيع طبية MeSH: MicroRNAs*/genetics , Prostatic Neoplasms*/diagnosis , Prostatic Neoplasms*/genetics , Prostatic Neoplasms*/pathology, Biomarkers, Tumor/genetics ; Humans ; Liquid Biopsy ; Male ; Prognosis ; Prostate-Specific Antigen
مستخلص: Purpose: Prostate cancer (PCa) is the 4th most diagnosed cancer and the 8th leading cause of cancer-related death worldwide. Currently, clinical risk stratification models including factors like PSA levels, Gleason score, and digital rectal examination are used for this purpose. There is a need for novel biomarkers that can distinguish between indolent and aggressive pathology and reduce the risk of overdiagnosis/overtreatment. Liquid biopsy has a non-invasive character, can lead to less morbidity and provide new biomarkers, such as miRNAs, that regulate diverse important cellular processes. Here, we report an extended revision about the role of cell-free and exosomal miRNAs (exomiRNAs) as biomarkers for screening, diagnosis, prognosis, or treatment of PCa.
Methods: A comprehensive review of the published literature was conducted focusing on the usefulness, advantages, and clinical applications of cell-free and exomiRNAs in serum and plasma. Using PubMed database 53 articles published between 2012 and 2021 were selected and discussed from the perspective of their use as diagnostic, prognostic and therapeutic biomarkers for PCa.
Results: We identify 119 miRNAs associated with PCa development and the cell-free and exosomal miR-21, miR-141, miR-200c, and miR-375 were consistently associated with progression in multiple cohorts/studies. However, standardized experimental procedures, and well-defined and clinically relevant cohort studies are urgently needed to confirm the biomarker potential of cell-free and exomiRNAs in serum or plasma.
Conclusion: Cell-free and exomiRNAs in serum or plasma are promising tools for be used as non-invasive biomarkers for diagnostic, prognosis, therapy improvement and clinical outcome prediction in PCa patients.
(© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
References: Aghdam AM, Amiri A, Salarinia R et al (2019) MicroRNAs as diagnostic, prognostic, and therapeutic biomarkers in prostate cancer. Crit Rev Eukaryot Gene Expr 29:127–139. https://doi.org/10.1615/CritRevEukaryotGeneExpr.2019025273. (PMID: 10.1615/CritRevEukaryotGeneExpr.201902527331679268)
Alhasan AH, Scott AW, Wu JJ et al (2016) Circulating microRNA signature for the diagnosis of very high-risk prostate cancer. Proc Natl Acad Sci USA 113:10655–10660. https://doi.org/10.1073/pnas.1611596113. (PMID: 10.1073/pnas.1611596113276016385035901)
Alix-panabières C, Pantel K (2016) Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov 6:479–492. https://doi.org/10.1158/2159-8290.CD-15-1483. (PMID: 10.1158/2159-8290.CD-15-148326969689)
Al-Qatati A, Akrong C, Stevic I et al (2017) Plasma microRNA signature is associated with risk stratification in prostate cancer patients. Int J Cancer 141:1231–1239. https://doi.org/10.1002/ijc.30815. (PMID: 10.1002/ijc.3081528571116)
Andl T, Ganapathy K, Bossan A, Chakrabarti R (2020) MicroRNAs as guardians of the prostate: those who stand before cancer. What do we really know about the role of microRNAs in prostate biology? Int J Mol Sci 21:1–33. (PMID: 10.3390/ijms21134796)
Armand-Labit V, Pradines A (2017) Circulating cell-free microRNAs as clinical cancer biomarkers. Biomol Concepts 8:61–81. https://doi.org/10.1515/bmc-2017-0002. (PMID: 10.1515/bmc-2017-000228448269)
Arrighetti N, Beretta GL (2021) Mirnas as therapeutic tools and biomarkers for prostate cancer. Pharmaceutics 13:1–26. https://doi.org/10.3390/pharmaceutics13030380. (PMID: 10.3390/pharmaceutics13030380)
Bardelli A, Pantel K (2017) Perspective Liquid Biopsies, What We Do Not Know ( Yet ). Cancer Cell 31:172–179. https://doi.org/10.1016/j.ccell.2017.01.002. (PMID: 10.1016/j.ccell.2017.01.00228196593)
Benoist GE, van Oort IM, Boerrigter E et al (2020) Prognostic Value of Novel Liquid Biomarkers in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide: A Prospective Observational Study. Clin Chem 66:842–851. https://doi.org/10.1093/clinchem/hvaa095. (PMID: 10.1093/clinchem/hvaa09532408351)
Berleman J, Auer M (2013) The role of bacterial outer membrane vesicles for intra- and interspecies delivery. Environ Microbiol 15:347–354. https://doi.org/10.1111/1462-2920.12048. (PMID: 10.1111/1462-2920.1204823227894)
Berman DM, Epstein JI (2014) When is prostate cancer really cancer? Urol Clin North Am 41:339–346. https://doi.org/10.1016/j.ucl.2014.01.006. (PMID: 10.1016/j.ucl.2014.01.00624725494)
Berti FCB, Salviano-Silva A, Beckert HC et al (2019) From squamous intraepithelial lesions to cervical cancer: Circulating microRNAs as potential biomarkers in cervical carcinogenesis. Biochim Biophys Acta - Rev Cancer 1872:18830–18836. https://doi.org/10.1016/j.bbcan.2019.08.001. (PMID: 10.1016/j.bbcan.2019.08.001)
Bhagirath D, Yang TL, Bucay N et al (2018) microRNA-1246 is an exosomal biomarker for aggressive prostate cancer. Cancer Res 78:1833–1844. https://doi.org/10.1158/0008-5472.CAN-17-2069. (PMID: 10.1158/0008-5472.CAN-17-2069294370395890910)
Brinton LT, Sloane HS, Kester M, Kelly KA (2015) Formation and role of exosomes in cancer. Cell Mol Life Sci 72:659–671. https://doi.org/10.1007/s00018-014-1764-3. (PMID: 10.1007/s00018-014-1764-325336151)
Bryant RJ, Pawlowski T, Catto JWF et al (2012) Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer 106:768–774. https://doi.org/10.1038/bjc.2011.595. (PMID: 10.1038/bjc.2011.595222407883322952)
Campos-Fernández E, Barcelos LS, de Souza AG et al (2019) Research landscape of liquid biopsies in prostate cancer. Am J Cancer Res 9:1309–1328. (PMID: 313920726682718)
Chen Y, Zhang L (2017) Members of the microRNA-200 family are promising therapeutic targets in cancer (Review). Exp Ther Med 14:10–17. https://doi.org/10.3892/etm.2017.4488. (PMID: 10.3892/etm.2017.4488286728875488420)
Cheng HH, Plets M, Li H et al (2018) Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate 78:121–127. https://doi.org/10.1002/pros.23452. (PMID: 10.1002/pros.2345229105802)
Cheng HH, Mitchell PS, Kroh EM et al (2013) Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia. PLoS ONE 8:e69239 https://doi.org/10.1371/journal.pone.0069239.
Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A (2013) Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol 10:472–484. https://doi.org/10.1038/nrclinonc.2013.110. (PMID: 10.1038/nrclinonc.2013.11023836314)
Cui M, Wang H, Yao X et al (2019) Circulating microRNAs in cancer: potential and challenge. Front Genet 10:472. https://doi.org/10.3389/fgene.2019.00626. (PMID: 10.3389/fgene.2019.00626)
de Broe ME, Wieme RJ, Logghe GN, Roels F (1977) Spontaneous shedding of plasma membrane fragments by human cells in vivo and in vitro. Clin Chim Acta 81:237–245. https://doi.org/10.1016/0009-8981(77)90054-7. (PMID: 10.1016/0009-8981(77)90054-7923096)
de Nóbrega M, Cilião HL, de Souza MF et al (2020) Association of polymorphisms of pten, akt1, pi3k, ar, and amacr genes in patients with prostate cancer. Genet Mol Biol 43:1–11. https://doi.org/10.1590/1678-4685-gmb-2018-0329. (PMID: 10.1590/1678-4685-gmb-2018-0329)
de Rubis G, Rajeev Krishnan S, Bebawy M (2019) Liquid biopsies in cancer diagnosis, monitoring, and prognosis. Trends Pharmacol Sci 40:172–186. https://doi.org/10.1016/j.tips.2019.01.006. (PMID: 10.1016/j.tips.2019.01.00630736982)
Di Meo A, Bartlett J, Cheng Y et al (2017) Liquid biopsy: a step forward towards precision medicine in urologic malignancies. Mol Cancer 16:1–14. https://doi.org/10.1186/s12943-017-0644-5. (PMID: 10.1186/s12943-017-0644-5)
Diamandis M, White NMA, Yousef GM (2010) Personalized medicine: marking a new epoch in cancer patient management. Mol Cancer Res 8:1175–1187. https://doi.org/10.1158/1541-7786.MCR-10-0264. (PMID: 10.1158/1541-7786.MCR-10-026420693306)
Eeles R, Raghallaigh HN (2017) Men with a susceptibility to prostate cancer and the role of genetic based screening. Transl Androl Urol 7: 61–69. https://doi.org/10.21037/tau.2017.12.30.
Egidi MG, Cochetti G, Serva MR et al (2013) Circulating microRNAs and Kallikreins before and after radical prostatectomy: are they really prostate cancer markers? Biomed Res Int 2013:1–11. https://doi.org/10.1155/2013/241780. (PMID: 10.1155/2013/241780)
Elewaily MI, Elsergany AR (2021) Emerging role of exosomes and exosomal microRNA in cancer: pathophysiology and clinical potential. J Cancer Res Clin Oncol 147:637–648. https://doi.org/10.1007/s00432-021-03534-5. (PMID: 10.1007/s00432-021-03534-533511427)
Endzeliņš E, Melne V, Kalniņa Z et al (2016) Diagnostic, prognostic and predictive value of cell-free miRNAs in prostate cancer : a systematic review. Mol Cancer 15:1–13. https://doi.org/10.1186/s12943-016-0523-5. (PMID: 10.1186/s12943-016-0523-5)
Endzelinš E, Berger A, Melne V et al (2017) Detection of circulating miRNAs: comparative analysis of extracellular vesicle-incorporated miRNAs and cell-free miRNAs in whole plasma of prostate cancer patients. BMC Cancer 17:1–13. https://doi.org/10.1186/s12885-017-3737-z. (PMID: 10.1186/s12885-017-3737-z)
Epstein JI, Zelefskyb MJ, Sjobergb DD et al (2016) Epstein 2016 a contemporary prostate cancer grading system.pdf. Eur Urol 69:428–435. https://doi.org/10.1016/j.eururo.2015.06.046.A. (PMID: 10.1016/j.eururo.2015.06.046.A26166626)
Farina NH, Wood ME, Perrapato SD et al (2014) Standardizing analysis of circulating microRNA: clinical and biological relevance. J Cell Biochem 115:805–811. https://doi.org/10.1002/jcb.24745. (PMID: 10.1002/jcb.24745243575373992702)
Farran B, Dyson G, Craig D et al (2018) A study of circulating microRNAs identifies a new potential biomarker panel to distinguish aggressive prostate cancer. Carcinogenesis 39:556–561. https://doi.org/10.1093/carcin/bgy025. (PMID: 10.1093/carcin/bgy025294714176853653)
Fernández-Lázaro D, Hernández JLG, García AC et al (2020) Liquid biopsy as novel tool in precision medicine: origins, properties, identification and clinical perspective of cancer’s biomarkers. Diagnostics 10:1–17. https://doi.org/10.3390/diagnostics10040215. (PMID: 10.3390/diagnostics10040215)
Ferreira MM, Ramani VC, Jeffrey SS (2016) Circulating tumor cell technologies. Mol Oncol 3:374–394. https://doi.org/10.1016/j.molonc.2016.01.007. (PMID: 10.1016/j.molonc.2016.01.007)
Fredsøe J, Rasmussen AKI, Mouritzen P et al (2020) Profiling of circulating microRNAs in prostate cancer reveals diagnostic biomarker potential. Diagnostics 10:1–13. https://doi.org/10.3390/diagnostics10040188. (PMID: 10.3390/diagnostics10040188)
Gandellini P, Ciniselli CM, Rancati T et al (2021) Prediction of grade reclassification of prostate cancer patients on active surveillance through the combination of a three-mirna signature and selected clinical variables. Cancers (basel) 13:1–13. https://doi.org/10.3390/cancers13102433. (PMID: 10.3390/cancers13102433)
Ge Y, Wang Q, Shao W et al (2020) Circulating let-7f-5p improve risk prediction of prostate cancer in patients with benign prostatic hyperplasia. J Cancer 11:4542–4549. https://doi.org/10.7150/jca.45077. (PMID: 10.7150/jca.45077324894717255360)
Glinge C, Clauss S, Boddum K et al (2017) Stability of circulating blood-based microRNAs-pre-analytic methodological considerations. PLoS ONE 12:1–16. https://doi.org/10.1371/journal.pone.0167969. (PMID: 10.1371/journal.pone.0167969)
Guan Y, Wu Y, Liu Y et al (2016) Association of microRNA-21 expression with clinicopathological characteristics and the risk of progression in advanced prostate cancer patients receiving androgen deprivation therapy. Prostate 76:986–993. https://doi.org/10.1002/pros.23187. (PMID: 10.1002/pros.2318727040772)
Ha M, Kim VN (2014) Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol 15:509–524. https://doi.org/10.1038/nrm3838. (PMID: 10.1038/nrm383825027649)
Han X, Wang J, Sun Y (2017) Circulating tumor DNA as biomarkers for cancer detection. Genom, Proteom Bioinf 15:59–72. https://doi.org/10.1016/j.gpb.2016.12.004. (PMID: 10.1016/j.gpb.2016.12.004)
Harding C, Heuser J, Stahl P (1983) Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. J Cell Biol 97:329–339. https://doi.org/10.1083/jcb.97.2.329. (PMID: 10.1083/jcb.97.2.3296309857)
Hoey C, Liu SK (2019) Circulating blood miRNAs for prostate cancer risk stratification: mirroring the underlying tumor biology with liquid biopsies. Res Reports Urol 11:29–42. https://doi.org/10.2147/RRU.S165625. (PMID: 10.2147/RRU.S165625)
Howe EN, Cochrane DR, Richer JK (2012) The miR-200 and miR-221/222 microRNA families: opposing effects on epithelial identity. J Mammary Gland Biol Neoplasia 17:65–77. https://doi.org/10.1007/s10911-012-9244-6. (PMID: 10.1007/s10911-012-9244-6223509804561555)
Huang X, Yuan T, Tschannen M et al (2013) Characterization of human plasma-derived exosomal RNAs by deep sequencing. BMC Genomics 14:1–14. https://doi.org/10.1186/1471-2164-14-319. (PMID: 10.1186/1471-2164-14-319)
Huang X, Yuana T, Liangc M et al (2015) Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancers. Eur Urol 67:33–41. https://doi.org/10.1016/j.eururo.2014.07.035.Exosomal. (PMID: 10.1016/j.eururo.2014.07.035.Exosomal25129854)
Ibrahim NH, Abdellateif MS, Ahmed M et al (2019) Diagnostic significance of miR - 21, miR - 141, miR - 18a and miR - 221 as novel biomarkers in prostate cancer among Egyptian patients. Andrologia 2019:1–9. https://doi.org/10.1111/and.13384. (PMID: 10.1111/and.13384)
Jiang S (2019) A regulator of metabolic reprogramming: MicroRNA Let-7. Transl Oncol 12:1005–1013. https://doi.org/10.1016/j.tranon.2019.04.013. (PMID: 10.1016/j.tranon.2019.04.013311284296531867)
Jones DZ, Schmidt ML, Suman S et al (2018) Micro-RNA-186-5p inhibition attenuates proliferation, anchorage independent growth and invasion in metastatic prostate cancer cells. BMC Cancer 18:1–16. https://doi.org/10.1186/s12885-018-4258-0. (PMID: 10.1186/s12885-018-4258-0)
Kachakova D, Mitkova A, Popov E et al (2015) Combinations of serum prostate-specific antigen and plasma expression levels of let-7c, miR-30c, miR-141, and miR-375 as potential better diagnostic biomarkers for prostate cancer. DNA Cell Biol 34:189–200. https://doi.org/10.1089/dna.2014.2663. (PMID: 10.1089/dna.2014.2663255214814337462)
Kasahara K, Taguchi T, Yamasaki I et al (2002) Detection of genetic alterations in advanced prostate cancer by comparative genomic hybridization. Cancer Genet Cytogenet 137:59–63. https://doi.org/10.1016/S0165-4608(02)00552-6. (PMID: 10.1016/S0165-4608(02)00552-612377415)
Katsogiannou M, Ziouziou H, Karaki S et al (2015) The hallmarks of castration-resistant prostate cancers. Cancer Treat Rev 41:588–597. https://doi.org/10.1016/j.ctrv.2015.05.003. (PMID: 10.1016/j.ctrv.2015.05.00325981454)
Keller S, Ridinger J, Rupp AK et al (2011) Body fluid derived exosomes as a novel template for clinical diagnostics. J Transl Med 9:1–9. https://doi.org/10.1186/1479-5876-9-86. (PMID: 10.1186/1479-5876-9-86)
Khan AQ, Ahmed EI, Elareer NR et al (2019) Role of miRNA-regulated cancer stem cells in the pathogenesis of human malignancies. Cells 8:1–33. https://doi.org/10.3390/cells8080840. (PMID: 10.3390/cells8080840)
Knyazev EN, Fomicheva KA, Mikhailenko DS et al (2016) Plasma levels of hsa-miR-619-5p and hsa-miR-1184 differ in prostatic benign hyperplasia and cancer. Bull Exp Biol Med 161:108–111. https://doi.org/10.1007/s10517-016-3357-7. (PMID: 10.1007/s10517-016-3357-727265125)
Kotb S, Mosharafa A, Essawi M et al (2014) Circulating miRNAs 21 and 221 as biomarkers for early diagnosis of prostate cancer. Tumor Biol 35:12613–12617. https://doi.org/10.1007/s13277-014-2584-7. (PMID: 10.1007/s13277-014-2584-7)
Lee I, Baxter D, Lee MY et al (2017) The importance of standardization on analyzing circulating RNA. Mol Diagnosis Ther 21:259–268. https://doi.org/10.1007/s40291-016-0251-y. (PMID: 10.1007/s40291-016-0251-y)
Leongamornlert D, Saunders E, Dadaev T et al (2014) Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease. Br J Cancer 110:1663–1672. https://doi.org/10.1038/bjc.2014.30. (PMID: 10.1038/bjc.2014.30245566213960610)
Li M, Rai AJ, Joel DeCastro G et al (2015a) An optimized procedure for exosome isolation and analysis using serum samples: application to cancer biomarker discovery. Methods 87:26–30. https://doi.org/10.1016/j.ymeth.2015.03.009. (PMID: 10.1016/j.ymeth.2015.03.00925814440)
Li Z, Ma YY, Wang J et al (2015b) Exosomal microRNA-141 is upregulated in the serum of prostate cancer patients. Onco Targets Ther 9:139–148. https://doi.org/10.2147/OTT.S95565. (PMID: 10.2147/OTT.S95565267700634706124)
Li Z, Ma Y, Wang J et al (2016) Exosomal microRNA-141 is upregulated in the serum of prostate cancer patients. Onco Targets Ther 16:139–148.
Li Z, Xu R, Li N (2018) MicroRNAs from plants to animals, do they define a new messenger for communication? Nutr Metab (lond) 15:1–21. https://doi.org/10.1186/s12986-018-0305-8. (PMID: 10.1186/s12986-018-0305-8)
Li W, Dong Y, Wang KJ et al (2020) Plasma exosomal miR-125a-5p and miR-141-5p as non-invasive biomarkers for prostate cancer. Neoplasma 67:1314–1318. https://doi.org/10.4149/neo. (PMID: 10.4149/neo32614237)
Lin HM, Castillo L, Mahon KL et al (2014) Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer. Br J Cancer 110:2462–2471. https://doi.org/10.1038/bjc.2014.181. (PMID: 10.1038/bjc.2014.181247147544021524)
Lin HM, Mahon KL, Spielman C et al (2017) Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer. Br J Cancer 116:1002–1011. https://doi.org/10.1038/bjc.2017.50. (PMID: 10.1038/bjc.2017.50282785155396108)
Liskova A, Samec M, Koklesova L et al (2020) Liquid biopsy is instrumental for 3PM dimensional solutions in cancer management. J Clin Med 9:2749. https://doi.org/10.3390/jcm9092749. (PMID: 10.3390/jcm90927497563444)
Liu RSC, Olkhov-Mitsel E, Jeyapala R et al (2018) Assessment of serum microRNA biomarkers to predict reclassification of prostate cancer in patients on active surveillance. J Urol 199:1475–1481. https://doi.org/10.1016/j.juro.2017.12.006. (PMID: 10.1016/j.juro.2017.12.00629246734)
Lockett KL, Snowhite IV, Hu JJ (2005) Nucleotide-excision repair and prostate cancer risk. Cancer Lett 220:125–135. https://doi.org/10.1016/j.canlet.2004.08.019. (PMID: 10.1016/j.canlet.2004.08.01915766587)
Lorenc T, Klimczyk K, Michalczewska I et al (2020) Exosomes in prostate cancer diagnosis, prognosis and therapy. Int J Mol Sci 21:1–14. https://doi.org/10.3390/ijms21062118. (PMID: 10.3390/ijms21062118)
Ludwig AK, Giebel B (2012) Exosomes: small vesicles participating in intercellular communication. Int J Biochem Cell Biol 44:11–15. https://doi.org/10.1016/j.biocel.2011.10.005. (PMID: 10.1016/j.biocel.2011.10.00522024155)
Lynch HT, Kosoko-lasaki O, Leslie SW et al (2015) Screening for familial and hereditary prostate cancer. Int J Cancer 138:2579–2591. https://doi.org/10.1002/ijc.29949. (PMID: 10.1002/ijc.29949)
Majid S, Dar AA, Saini S et al (2013) MicroRNA-34b inhibits prostate cancer through demethylation, active chromatin modifications and AKT pathways. Clin Cancer Res 19:73–84. https://doi.org/10.1158/1078-0432.CCR-12-2952. (PMID: 10.1158/1078-0432.CCR-12-295223147995)
Malla B, Aebersold DM, Dal Pra A (2018) Protocol for serum exosomal miRNAs analysis in prostate cancer patients treated with radiotherapy. J Transl Med 16:1–13. https://doi.org/10.1186/s12967-018-1592-6. (PMID: 10.1186/s12967-018-1592-6)
Marrugo-Ramírez J, Mir M, Samitier J (2018) Blood-based cancer biomarkers in liquid biopsy: a promising non-invasive alternative to tissue biopsy. Int J Mol Sci 19:1–21. https://doi.org/10.3390/ijms19102877. (PMID: 10.3390/ijms19102877)
Matsuzaki K, Fujita K, Tomiyama E, et al (2021) MiR-30b-3p and miR-126–3p of urinary extracellular vesicles could be new biomarkers for prostate cancer. Transl Androl Urol 10 :1918–1927. https://doi.org/10.21037/tau-20-421.
McDonald JS, Milosevic D, Reddi HV et al (2011) Analysis of circulating microRNA: preanalytical and analytical challenges. Clin Chem 57:833–840. https://doi.org/10.1373/clinchem.2010.157198. (PMID: 10.1373/clinchem.2010.15719821487102)
McDonald AC, Vira M, Walter V et al (2019) Circulating microRNAs in plasma among men with low-grade and high-grade prostate cancer at prostate biopsy. Prostate 79:961–968. https://doi.org/10.1002/pros.23803. (PMID: 10.1002/pros.23803309589106520194)
Mello-Grand M, Gregnanin I, Sacchetto L et al (2020) Circulating microRNAs combined with PSA for accurate and non-invasive prostate cancer detection. Cancer 46:1–17.
Mihelich BL, Maranville JC, Nolley R et al (2015) Elevated serum microRNA levels associate with absence of high-grade prostate cancer in a retrospective cohort. PLoS ONE 10:1–15. https://doi.org/10.1371/journal.pone.0124245. (PMID: 10.1371/journal.pone.0124245)
Mitchell PS, Parkin RK, Kroh EM et al (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105:10513–10518. https://doi.org/10.1073/pnas.0804549105. (PMID: 10.1073/pnas.0804549105186632192492472)
Mottet N, Bellmunt J, Bolla M et al (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 71:618–629. https://doi.org/10.1016/j.eururo.2016.08.003. (PMID: 10.1016/j.eururo.2016.08.00327568654)
Moustafa AA, Kim H, Albeltagy RS et al (2018) MicroRNAs in prostate cancer: from function to biomarker discovery. Exp Biol Med 243:817–825. https://doi.org/10.1177/1535370218775657. (PMID: 10.1177/1535370218775657)
Mussbacher M, Krammer TL, Heber S et al (2020) The quantification of human blood-derived microRNA signatures. Cells 9:1–14. https://doi.org/10.3390/cells9081915. (PMID: 10.3390/cells9081915)
Nguyen HCN, Xie W, Yang M et al (2013) Expression differences of circulating MicroRNAs in metastastic castration resistant prostate cancer and low-risk, localized prostate cancer. Prostate 73:346–354. https://doi.org/10.1002/pros.22572. (PMID: 10.1002/pros.2257222887127)
O’Brien J, Hayder H, Zayed Y, Peng C (2018) Overview of microRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol (lausanne) 9:1–12. https://doi.org/10.3389/fendo.2018.00402. (PMID: 10.3389/fendo.2018.00402)
O’Connor MJ (2015) Targeting the DNA damage response in cancer. Mol Cell 60:547–560. https://doi.org/10.1016/j.molcel.2015.10.040. (PMID: 10.1016/j.molcel.2015.10.04026590714)
Oliver SJ, de Bono S (2018) Metastatic prostate cancer. New Engl J Med 378:645–657. https://doi.org/10.1056/NEJMra1701695. (PMID: 10.1056/NEJMra1701695)
Ortiz-Quintero B (2016) Cell-free microRNAs in blood and other body fluids, as cancer biomarkers. Cell Prolif 49:281–303. https://doi.org/10.1111/cpr.12262. (PMID: 10.1111/cpr.12262272186646496612)
Osip’yantsKnyazevGalatenko AIENAV et al (2017) Changes in the level of circulating hsa-miR-297 and hsa-miR-19b-3p miRNA are associated with generalization of prostate cancer. Bull Exp Biol Med 162:379–382. https://doi.org/10.1007/s10517-017-3620-6. (PMID: 10.1007/s10517-017-3620-6)
Osipov ID, Zaporozhchenko IA, Bondar AA, et al (2016) Cell-Free miRNA-141 and miRNA-205 as Prostate Cancer Biomarkers. In: Advances in Experimental Medicine and Biology. Springer Nature, pp 9–12.
Otmani K, Lewalle P (2021) Tumor suppressor miRNA in cancer cells and the tumor microenvironment: mechanism of deregulation and clinical implications. Front Oncol 11:1–15. https://doi.org/10.3389/fonc.2021.708765. (PMID: 10.3389/fonc.2021.708765)
Ozawa PMM, Jucoski TS, Vieira E et al (2020) Liquid biopsy for breast cancer using extracellular vesicles and cell-free microRNAs as biomarkers. Transl Res 223:40–60. https://doi.org/10.1016/j.trsl.2020.04.002. (PMID: 10.1016/j.trsl.2020.04.00232413499)
Page K, Guttery DS, Zahra N et al (2013) Influence of plasma processing on recovery and analysis of circulating nucleic acids. PLoS ONE 8:2–11. https://doi.org/10.1371/journal.pone.0077963. (PMID: 10.1371/journal.pone.0077963)
Panigrahi GK, Ramteke A, Birks D, et al (2018) Exosomal microRNA profiling to identify hypoxia-related biomarkers in prostate cancer. Oncotarget 9:13894–13910. https://doi.org/10.18632/oncotarget.24532.
Paschalis A, de Bono JS (2020) Prostate Cancer 2020: “The Times They Are a’Changing.” Cancer Cell 38:25–27. https://doi.org/10.1016/j.ccell.2020.06.008. (PMID: 10.1016/j.ccell.2020.06.00832663466)
Pastor-Navarro B, García-Flores M, Fernández-Serra A et al (2020) A tetra-panel of serum circulating mirnas for the diagnosis of the four most prevalent tumor types. Int J Mol Sci 21:1–13. https://doi.org/10.3390/ijms21082783. (PMID: 10.3390/ijms21082783)
Porkka KP, Pfeiffer MJ, Waltering KK et al (2007) MicroRNA expression profiling in prostate cancer. Cancer Res 67:6130–6135. https://doi.org/10.1158/0008-5472.CAN-07-0533. (PMID: 10.1158/0008-5472.CAN-07-053317616669)
Porzycki P, Ciszkowicz E, Semik M, Tyrka M (2018) Combination of three miRNA (miR-141, miR-21, and miR-375) as potential diagnostic tool for prostate cancer recognition. Int Urol Nephrol 50:1619–1626. https://doi.org/10.1007/s11255-018-1938-2. (PMID: 10.1007/s11255-018-1938-2300144596133127)
Rajagopal C, Harikumar KB (2018) The origin and functions of exosomes in cancer. Front Oncol 8:1–13. https://doi.org/10.3389/fonc.2018.00066. (PMID: 10.3389/fonc.2018.00066)
Rajendiran S, Maji S, Haddad A et al (2021) MicroRNA-940 as a potential serum biomarker for prostate cancer. Front Oncol 11:1–10. https://doi.org/10.3389/fonc.2021.628094. (PMID: 10.3389/fonc.2021.628094)
Raposo G, Stoorvogel W (2013) Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol 200:373–383. https://doi.org/10.1083/jcb.201211138. (PMID: 10.1083/jcb.201211138234208713575529)
Rawla P (2019) Epidemiology of prostate cancer. Pathol Epidemiol Cancer. 10:63–89 https://doi.org/10.14740/wjon1191.
Rebbeck TR (2017) Prostate cancer genetics: variation by race, ethnicity, and geography. Semin Radiat Oncol 27:3–10. https://doi.org/10.1016/j.semradonc.2016.08.002.Prostate. (PMID: 10.1016/j.semradonc.2016.08.002.Prostate27986209)
Ribas J, Lupold SE (2010) The transcriptional regulation of miR-21, its multiple transcripts, and their implication in prostate cancer. Cell Cycle 9:923–929. https://doi.org/10.4161/cc.9.5.10930. (PMID: 10.4161/cc.9.5.1093020160498)
Ruivo CF, Adem B, Silva M, Melo SA (2017) The biology of cancer exosomes: insights and new perspectives. Cancer Res 77:6480–6489. https://doi.org/10.1158/0008-5472.CAN-17-0994. (PMID: 10.1158/0008-5472.CAN-17-099429162616)
Rupaimoole R, Calin GA, Lopez-Berestein G, Sood AK (2016) MicroRNA deregulation in cancer cells and the tumor microenvironment. Cancer Discov 6:235–246. https://doi.org/10.1158/2159-8290.CD-15-0893. (PMID: 10.1158/2159-8290.CD-15-0893268652494783232)
Salvianti F, Gelmini S, Costanza F et al (2020) The pre-analytical phase of the liquid biopsy. N Biotechnol 55:19–29. https://doi.org/10.1016/j.nbt.2019.09.006. (PMID: 10.1016/j.nbt.2019.09.00631580920)
Sanhueza C, Kohli M (2018) Clinical and novel biomarkers in the management of prostate cancer. Curr Treat Options Oncol 19:1–17. https://doi.org/10.1007/s11864-018-0527-z. (PMID: 10.1007/s11864-018-0527-z)
Sathianathen NJ, Konety BR, Crook J et al (2018) Landmarks in prostate cancer. Nat Rev Urol 15:627–642. https://doi.org/10.1038/s41585-018-0060-7. (PMID: 10.1038/s41585-018-0060-730065357)
Schaeffer E, Srinivas S, Antonarakis ES et al (2021) Prostate cancer, version 1.2021: featured updates to the NCCN guidelines. JNCCN J Natl Compr Cancer Netw 19:134–143. https://doi.org/10.6004/jnccn.2021.0028. (PMID: 10.6004/jnccn.2021.0028)
Schwarzenbach H, Hoon DSB, Pantel K (2011) Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 11:426–437. https://doi.org/10.1038/nrc3066. (PMID: 10.1038/nrc306621562580)
Sekhon K, Bucay N, Majid S, Dahiya R (2016) MicroRNAs and epithelial-mesenchymal transition in prostate cancer. Oncotarget 7:67597–67611. https://doi.org/10.18632/oncotarget.11708.
Selth LA, Townley SL, Bert AG et al (2013) Circulating microRNAs predict biochemical recurrence in prostate cancer patients. Br J Cancer 109:641–650. https://doi.org/10.1038/bjc.2013.369. (PMID: 10.1038/bjc.2013.369238461693738112)
Sharma P, Diergaarde B, Ferrone S et al (2020) Melanoma cell-derived exosomes in plasma of melanoma patients suppress functions of immune effector cells. Sci Rep 10:1–11. https://doi.org/10.1038/s41598-019-56542-4. (PMID: 10.1038/s41598-019-56542-4)
Shkurnikov Y, Makarova YA, Knyazev EN et al (2016) Plasma levels of hsa-miR-619-5p and hsa-miR-1184 differ in prostatic benign hyperplasia and cancer. Bull Exp Biol Med 161:108–111. https://doi.org/10.1007/s10517-016-3357-7. (PMID: 10.1007/s10517-016-3357-727265125)
Shkurnikov MY, Makarova YA, Knyazev EN et al (2017) Plasma Level of hsa-miR-619-5p microRNA is associated with prostatic cancer dissemination beyond the capsule. Bull Exp Biol Med 163:475–477. https://doi.org/10.1007/s10517-017-3831-x. (PMID: 10.1007/s10517-017-3831-x28853076)
Siegel R, Ma J, Zou Z (2014) Jemal A (2014) Cancer statistics. CA Cancer J Clin 64:9–29. https://doi.org/10.3322/caac.21208. (PMID: 10.3322/caac.2120824399786)
Siravegna G, Marsoni S, Siena S, Bardelli A (2017) Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol 14:531–548. https://doi.org/10.1038/nrclinonc.2017.14. (PMID: 10.1038/nrclinonc.2017.1428252003)
Sokolova V, Ludwig AK, Hornung S et al (2011) Characterisation of exosomes derived from human cells by nanoparticle tracking analysis and scanning electron microscopy. Colloids Surfaces B Biointerfaces 87:146–150. https://doi.org/10.1016/j.colsurfb.2011.05.013. (PMID: 10.1016/j.colsurfb.2011.05.01321640565)
Souza MF, Kuasne H, Barros-Filho MDC et al (2017) Circulating mRNAs and miRNAs as candidate markers for the diagnosis and prognosis of prostate cancer. PLoS ONE 12:1–16. https://doi.org/10.1371/journal.pone.0184094. (PMID: 10.1371/journal.pone.0184094)
Spahn M, Kneitz S, Scholz C-J et al (2010) Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int J Cancer 403:394–403. https://doi.org/10.1002/ijc.24715. (PMID: 10.1002/ijc.24715)
Stuopelyte K, Daniunaite K, Bakavicius A et al (2016) The utility of urine-circulating miRNAs for detection of prostate cancer. Br J Cancer 115:707–715. https://doi.org/10.1038/bjc.2016.233. (PMID: 10.1038/bjc.2016.233274908055023772)
Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660. (PMID: 10.3322/caac.2166033538338)
Swarup V, Rajeswari MR (2007) Circulating ( cell-free ) nucleic acids – A promising, non-invasive tool for early detection of several human diseases. FEBS Lett 581:795–799. https://doi.org/10.1016/j.febslet.2007.01.051. (PMID: 10.1016/j.febslet.2007.01.05117289032)
Takahashi K, Kanno SI, Mizuno K (2014) Activation of cytosolic Slingshot-1 phosphatase by gelsolin-generated soluble actin filaments. Biochem Biophys Res Commun 454:471–477. https://doi.org/10.1016/j.bbrc.2014.10.108. (PMID: 10.1016/j.bbrc.2014.10.10825451266)
Tang Y, Wu B, Huang S et al (2019) Downregulation of miR-505-3p predicts poor bone metastasis-free survival in prostate cancer. Oncol Rep 41:57–66. https://doi.org/10.3892/or.2018.6826. (PMID: 10.3892/or.2018.682630365141)
Théry C, Witwer KW, Aikawa E et al (2018) Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles 7:1–43. https://doi.org/10.1080/20013078.2018.1535750. (PMID: 10.1080/20013078.2018.1535750)
Thieu W, Tilki D, DeVere White RW, Evans CP (2014) The role of microRNA in castration-resistant prostate cancer. Urol Oncol Semin Orig Investig 32:517–523. https://doi.org/10.1016/j.urolonc.2013.11.004. (PMID: 10.1016/j.urolonc.2013.11.004)
Tinay I, Tan M, Gui B et al (2018) Functional roles and potential clinical application of miRNA-345-5p in prostate cancer. Prostate 78:927–937. https://doi.org/10.1002/pros.23650. (PMID: 10.1002/pros.2365029748958)
Torbati PM, Asadi F, Fard-Esfahani P (2019) Circulating miR-20a and miR-26a as biomarkers in prostate cancer. Asian Pacific J Cancer Prev 20:1453–1456. https://doi.org/10.31557/APJCP.2019.20.5.1453.
Urabe F, Matsuzaki J, Yamamoto Y et al (2019) Large-scale circulating microRNA profiling for the liquid biopsy of prostate cancer. Clin Cancer Res 25:3016–3025. https://doi.org/10.1158/1078-0432.CCR-18-2849. (PMID: 10.1158/1078-0432.CCR-18-284930808771)
Valentino A, Reclusa P, Sirera R et al (2017) Exosomal microRNAs in liquid biopsies: future biomarkers for prostate cancer. Clin Transl Oncol 19:651–657. https://doi.org/10.1007/s12094-016-1599-5. (PMID: 10.1007/s12094-016-1599-528054319)
Vargas AJ, Harris CC (2016) Biomarker development in the precision medicine era: lung cancer as a case study. Nat Rev Cancer 16:525–537. https://doi.org/10.1038/nrc.2016.56. (PMID: 10.1038/nrc.2016.56273886996662593)
Villarroya-Beltri C, Baixauli F, Gutiérrez-Vázquez C et al (2014) Sorting it out: regulation of exosome loading. Semin Cancer Biol 28:1–26. https://doi.org/10.1016/j.semcancer.2014.04.009. (PMID: 10.1016/j.semcancer.2014.04.009)
Wang K, Yuan Y, Cho JH et al (2012) Comparing the MicroRNA spectrum between serum and plasma. PLoS ONE 7:1–9. https://doi.org/10.1371/journal.pone.0041561. (PMID: 10.1371/journal.pone.0041561)
Wang J, Ye H, Zhang D et al (2016) MicroRNA-410-5p as a potential serum biomarker for the diagnosis of prostate cancer. Cancer Cell Int 16:1–6. https://doi.org/10.1186/s12935-016-0285-6. (PMID: 10.1186/s12935-016-0285-6)
Wang G, Zhao D, Spring DJ, Depinho RA (2018) Genetics and biology of prostate cancer. Genes Dev 32:1105–1140. https://doi.org/10.1101/gad.315739.118. (PMID: 10.1101/gad.315739.118301813596120714)
Weber JA, Baxter DH, Zhang S et al (2010) The microRNA spectrum in 12 body fluids. Clin Chem 56:1733–1741. https://doi.org/10.1373/clinchem.2010.147405. (PMID: 10.1373/clinchem.2010.147405208473274846276)
Westermann AM, Schmidt D, Holdenrieder S, et al (2014) Serum microRNAs as biomarkers in patients undergoing prostate biopsy: results from a prospective multi-center study. Anticancer Res 34:665–670.
Whiteside TL (2016) Tumor-derived exosomes and their role in cancer progression. Adv Clin Chem 74:103–141. https://doi.org/10.1016/bs.acc.2015.12.005. (PMID: 10.1016/bs.acc.2015.12.005271176625382933)
Willms E, Johansson HJ, Mäger I et al (2016) Cells release subpopulations of exosomes with distinct molecular and biological properties. Sci Rep 6:1–12. https://doi.org/10.1038/srep22519. (PMID: 10.1038/srep22519)
Yadav S, Anbalagan M, Baddoo M et al (2020) Somatic mutations in the DNA repairome in prostate cancers in African Americans and Caucasians. Oncogene 39:4299–4311. https://doi.org/10.1038/s41388-020-1280-x. (PMID: 10.1038/s41388-020-1280-x323001777239769)
Yu Q, Li P, Weng M et al (2018) Nano-vesicles are a potential tool to monitor therapeutic efficacy of carbon ion radiotherapy in prostate cancer. J Biomed Nanotechnol 14:168–178. https://doi.org/10.1166/jbn.2018.2503. (PMID: 10.1166/jbn.2018.250329463374)
Yu S, Cao H, Shen B, Feng J (2015) Tumor-derived exosomes in cancer progression and treatment failure. Oncotarget 6:37151–37168. https://doi.org/10.18632/oncotarget.6022.
Zedan AH, Hansen TF, Assenholt J et al (2019) Circulating miRNAs in localized/locally advanced prostate cancer patients after radical prostatectomy and radiotherapy. Prostate 79:425–432. https://doi.org/10.1002/pros.23748. (PMID: 10.1002/pros.2374830537232)
Zedan AH, Osther PJS, Assenholt J et al (2020) Circulating miR-141 and miR-375 are associated with treatment outcome in metastatic castration resistant prostate cancer. Sci Rep 10:1–9. https://doi.org/10.1038/s41598-019-57101-7. (PMID: 10.1038/s41598-019-57101-7)
Zhang S, Liu C, Zou X et al (2021) Microrna panel in serum reveals novel diagnostic biomarkers for prostate cancer. PeerJ 9:1–19. https://doi.org/10.7717/peerj.11441. (PMID: 10.7717/peerj.11441)
Zhou C, Chen Y, He X et al (2020) Functional implication of exosomal miR-217 and mir-23b-3p in the progression of prostate cancer. Onco Targets Ther 13:11595–11607. https://doi.org/10.2147/OTT.S272869. (PMID: 10.2147/OTT.S272869332090367670263)
Zidan HE, Abdul-Maksoud RS, Elsayed WSH, Desoky EAM (2018) Diagnostic and prognostic value of serum miR-15a and miR-16-1 expression among Egyptian patients with prostate cancer. IUBMB Life 70:437–444. https://doi.org/10.1002/iub.1733. (PMID: 10.1002/iub.173329522280)
معلومات مُعتمدة: Finance Code 001 Coordenação de Aperfeiçoamento de Pessoal de Nível Superior; 308231/2017-1 Conselho Nacional de Desenvolvimento Científico e Tecnológico
فهرسة مساهمة: Keywords: Biomarkers; Non-coding RNAs; Preclinical; Serum and plasma
المشرفين على المادة: 0 (Biomarkers, Tumor)
0 (MicroRNAs)
EC 3.4.21.77 (Prostate-Specific Antigen)
تواريخ الأحداث: Date Created: 20220803 Date Completed: 20220915 Latest Revision: 20220915
رمز التحديث: 20231215
DOI: 10.1007/s00432-022-04213-9
PMID: 35922694
قاعدة البيانات: MEDLINE
كن أول من يترك تعليقا!
يجب تسجيل دخولك أولا